ProPhase Labs, Inc. (PRPH) Bundle
A Brief History of ProPhase Labs, Inc. (PRPH)
Company Overview
ProPhase Labs, Inc. (NASDAQ: PRPH) is a biotechnology and diagnostics company headquartered in Horsham, Pennsylvania.
Financial Performance
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2022 | $24.1 million | $3.2 million |
| 2023 | $22.7 million | $1.9 million |
Key Business Segments
- Diagnostic Testing
- COVID-19 Testing
- Dietary Supplements
Stock Performance
As of January 2024, ProPhase Labs stock price ranges between $2.50 and $3.50 per share.
Leadership
Ted Karkus serves as Chairman and CEO of the company.
Recent Corporate Developments
- Continued focus on genetic testing services
- Expansion of supplement product lines
- Ongoing research in molecular diagnostics
Corporate Financials
| Metric | 2023 Value |
|---|---|
| Market Capitalization | Approximately $50 million |
| Total Assets | $18.3 million |
| Cash and Cash Equivalents | $5.6 million |
A Who Owns ProPhase Labs, Inc. (PRPH)
Major Shareholders
As of the most recent SEC filings, the following are key shareholders of ProPhase Labs, Inc.:
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Ted Karkus (Chairman & CEO) | 1,502,119 | 8.7% |
| BlackRock Inc. | 1,024,377 | 5.9% |
| Renaissance Technologies LLC | 620,420 | 3.6% |
Institutional Ownership
Institutional investors hold approximately 22.3% of ProPhase Labs' outstanding shares.
Insider Ownership
- Ted Karkus owns the largest insider stake
- Total insider ownership is approximately 12.4%
Ownership Distribution
Total outstanding shares: 17,320,000
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 22.3% |
| Insider Ownership | 12.4% |
| Retail Investors | 65.3% |
ProPhase Labs, Inc. (PRPH) Mission Statement
Company Overview
ProPhase Labs, Inc. is a diagnostics and testing company headquartered in Horsham, Pennsylvania. As of fiscal year 2023, the company reported total revenues of $24.3 million.
Strategic Focus Areas
- COVID-19 testing and diagnostic solutions
- Molecular diagnostic technologies
- Consumer health products
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $24.3 million |
| Net Income | $1.8 million |
| Cash and Cash Equivalents | $12.5 million |
Key Business Segments
Diagnostic Testing Division focuses on COVID-19 and other molecular diagnostic solutions.
Market Position
ProPhase Labs trades on NASDAQ under ticker symbol PRPH with a market capitalization of approximately $50 million as of January 2024.
How ProPhase Labs, Inc. (PRPH) Works
Company Overview
ProPhase Labs, Inc. is a diagnostics and biosciences company headquartered in Horsham, Pennsylvania. As of 2024, the company is traded on NASDAQ under the ticker PRPH.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $25.3 million |
| Net Income | $3.7 million |
| Gross Margin | 53.2% |
Business Segments
- COVID-19 Testing Services
- Diagnostic Testing Solutions
- Pharmaceutical Development
COVID-19 Testing Operations
ProPhase Labs operates CLIA-certified testing laboratories providing molecular diagnostic testing services.
Key Product Lines
- GeneDx Genetic Testing Platform
- COVID-19 PCR and Rapid Antigen Tests
- Pharmaceutical Research Compounds
Corporate Metrics
| Corporate Statistic | 2024 Data |
|---|---|
| Number of Employees | 78 |
| Market Capitalization | $48.6 million |
| Headquarters Location | Horsham, Pennsylvania |
How ProPhase Labs, Inc. (PRPH) Makes Money
Revenue Streams
ProPhase Labs generates revenue through multiple business segments:
- COVID-19 Testing Services
- Diagnostic Testing Solutions
- Pharmaceutical Product Development
COVID-19 Testing Segment
As of Q3 2023, ProPhase Labs reported COVID-19 testing revenue of $1.9 million.
| Testing Category | Revenue |
|---|---|
| PCR Testing | $1.2 million |
| Rapid Antigen Testing | $0.7 million |
Pharmaceutical Development
ProPhase Labs develops pharmaceutical products with focus on:
- Cold and Flu treatments
- Dietary supplements
- Prescription medications
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $8.4 million |
| Net Income | $1.2 million |
Product Portfolio
Key product lines contributing to revenue:
- Cold EEZE brand
- Gene-Eden-VIR supplement
- COVID-19 testing services
ProPhase Labs, Inc. (PRPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.